Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

Wet AMD affects approximately five million patients worldwide and this patient population is continuing to grow. Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, the central area of the retina responsible for detailed vision. These blood vessels are often fragile and can leak blood and fluid below the macula, causing damage to the photoreceptors and vision loss. AMD, a disease associated with aging, gradually destroys a patient's vision. It is the most common cause of vision loss in patients aged 50 or older, and represents a market of over $1 billion annually.

Abnormalities in the vitreomacular interface (the interface of the vitreous and macula) have been implicated in wet AMD, and recent publications have demonstrated that approximately one-third of AMD patients have focal vitreomacular adhesion (VMA). VMA is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye, and research has found that this adhesion occurs in the same location as the wet AMD pathology.[1]

ThromboGenics is developing microplasmin as a non-surgical treatment for vitreomacular adhesion. Microplasmin has the potential to separate the vitreous from the retina and, as wet AMD is thought to result from the abnormal connection of the vitreous to the retina, it is therefore anticipated that microplasmin could potentially prevent the progression of this highly prevalent disease.

The MIVI 5 (Microplasmin for IntraVitreous Injection) trial is a Phase II, randomized, double-blind, sham controlled trial of microplasmin intravitreal injection (125 μg) for the treatment of focal vitreomacular adhesion (separation of the vitreous from the retina) in patients with exudative (wet) AMD. The trial will enroll approximately 100 patients at up to 20 centers across five European countries. The primary endpoint of the trial is non-surgical resolution of vitreomacular adhesion, defined as the separation of the vitreous from the retina by 28 days. This will be assessed by the Central Reading Center based on optical coherence tomography (OCT) images. Additional measures of efficacy and safety will also be assessed over a one year follow-up period.

Microplasmin has the potential to transform the treatment of a number of other important back of the eye diseases as well as AMD. Microplasmin is currently being evaluated in a Phase III program of approximately 640 patients, for the non-surgical treatment of focal vitreomacular adhesion.

Dr. Patrik De Haes, CEO of ThromboGenics commenting on the announcement said, "We are very pleased to announce the start of a Phase II trial of microplasmin in such a significant condition as AMD. It is increasingly clear that vitreomacular adhesion plays a key role in AMD sufferers with a poorer prognosis. Microplasmin's potential to cleave the vitreous from the retina could therefore represent an important advance in the treatment of this patient group. The start of this trial underlines the potential broad applicability of our lead product, and is another important step as we create a profitable integrated company focused on cutting edge ophthalmic medicines."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    [1] Robison CD et al, 2009; Mojana J et al, 2008; Krebs I et al, 2007
    For further information please contact:


    Dr. Patrik De Haes, CEO                   Tel: + 32-16-75-13-1
    Dr. Steve Pakola, CMO                     Tel: +1(212)201-0920

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71

SOURCE ThromboGenics NV

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
(Date:10/9/2015)... -- Regulatory affairs groups within medical device organizations face a ... These specialized groups are charged with ensuring that their ... to the development and marketing of medical device products. While ... their own internal effectiveness and efficiencies to remain productive and ... --> Optimal resourcing and staffing help ...
(Date:10/9/2015)... MOUNT BRYDGES, Ontario , Oct. 9, ... of ergonomic radiology furniture, monitor mounting solutions ... Texas Children,s Hospital,s Department of Pediatric Radiology ... "ballroom concept."  RedRick Technologies provided ergonomic design ... facilitating productivity, clinical collaboration and teaching. ...
(Date:10/9/2015)... DIEGO , Oct. 9, 2015  The ... National Center for Emerging and Zoonotic Infectious Diseases, ... Genome have entered into a research collaboration to ... platform. The goal of this research collaboration is ... DRAGEN platform for public health and infectious disease ...
Breaking Medicine Technology:
... Nov. 6 Trius Therapeutics, Inc. announced today that it ... U.S. Securities and Exchange Commission (SEC) relating to a proposed ... shares of the common stock to be sold in the ... Securities (USA) LLC is acting as sole book-running manager, Piper ...
... and liquidations of trucking equipment and machine tools in ... similar figures from 2008, according to Nassau Asset Management,s ... the company,s activity reports for both repossessions and orderly ... construction and printing equipment, offering mixed news on the ...
Cached Medicine Technology:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern Pennsylvania personal injury ... by The National Law Journal for inclusion in their second annual list of ... United States who obtained the largest awards for their personal injury clients in ...
(Date:10/9/2015)... ... 09, 2015 , ... For many, October is a month whose focus has ... to find a cure. At Beverly Hills Physicians in Southern California, it is also ... Bra Collection Campaign, Beverly Hills Physicians is encouraging patients and non-patients alike to donate ...
(Date:10/9/2015)... ... October 09, 2015 , ... Advanced Hearing Solutions, Nashville ... annual Toast of Music City, a reader’s choice awards featuring favorite places to ... votes for their favorite businesses in over 200 categories, including best pizza, best ...
(Date:10/9/2015)... ... 2015 , ... The Asthma and Allergy Foundation of America (AAFA) has been ... (CDC) to improve the knowledge and skills of underserved adults with asthma. This is ... the CDC and allows AAFA to continue vital efforts to educate people living with ...
Breaking Medicine News(10 mins):
... N.J., Nov. 5 The results of a ... Democrats,and Independents revealed that while the majority of ... three years, they were divided on the,issue of ... ), The study was conducted by HCD ...
... U.S. Preventive Medicine(R), the leader,in disease prevention, ... Executive Vice President-Customer Service. In this newly-created,position, ... maximizing the,efficiency of all customer service activities ... employers, government, consumers, benefit brokers,and affinity partners. ...
... facility in Tanzania to,be honored with 2008 International ... Today, Seva,Foundation proudly honors the accomplishments of ... around the world -- Dr. Paul,Courtright and Dr. ... Community Ophthalmology (KCCO),which Courtright and Lewallen established in ...
... again received Full Accreditation by the National Committee for Quality ... congestive heart failure, chronic obstructive pulmonary disease (COPD), coronary artery ... ... Irvine, Calif. (Vocus) November 5, 2008-- LifeMasters Supported ...
... Training will prepare military recreation managers to assist service ... members returning ... More than 65,000 military,personnel have been wounded by hostile and ... advances in medical care, recreation,programming is playing an important role ...
... research team, led by Columbia University Medical Center, has ... cancer the second leading cause of cancer-related mortality ... time, that elevated levels of a single proinflammatory cytokine, ... start the progression towards stomach cancer. These results are ...
Cached Medicine News:
Rotating 360 degrees, 3 mm x 7 mm bite....
45 degree, forward 3 mm, 4 mm x 5 mm cup, length of shaft 140 mm, overall length 8.3 inches....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Small right. Teflon orbital plates....
Medicine Products: